News | September 05, 2025
Quotient Sciences and CPI join forces to accelerate RNA drug development
The partnership will create a first-of-its-kind, fully integrated offering for the development of mRNA drug products
The partnership will create a first-of-its-kind, fully integrated offering for the development of mRNA drug products
Up to $30m funding will be provided to advance an innovative vaccine technology that could protect against current and future SARS-CoV-2 variants and other SARS-like Betacoronaviruses.
KOREA PACK and concurrent event ICPI Week (Int’l Cosmetic and Pharmaceutical Industry Week) will be held as hybrid events in 2022
mRNA-4359 advances to phase 2 following encouraging results in checkpoint inhibitor-resistant Melanoma
Partners with Yifan Pharmaceutical to launch Synovian injection for osteoarthritis in China
Pelabresib recently met its primary endpoint of spleen volume reduction and demonstrated favorable trends in symptom improvement
XTANDI becomes the first and only androgen receptor signaling inhibitor approved for use with or without a GnRH analog therapy in nonmetastatic castration-sensitive prostate cancer
This project will aim to develop a next-generation A3 adenosine receptor drug agonists
Alnylam is the latest partner in the Medicines Manufacturing Innovation Centre’s third Grand Challenge project, which aims to revolutionise the manufacturing process for oligonucleotide therapies
Subscribe To Our Newsletter & Stay Updated
